title: Cellular and vaccine immunotherapy for multiple myeloma.
abstract: Allogeneic hematopoietic cell transplantation and donor lymphocyte infusion for multiple myeloma (MM) can induce graft-versus-myeloma immunity and long-term survivorship, but limited efficacy and associated toxicities have prevented its widespread use. Cellular immunotherapies and vaccines seek to induce more specific, reliable, and potent antimyeloma immune responses with less treatment-related risk than is possible with allogeneic transplantation. Advances in molecular biology, and basic and applied immunology, have led to promising approaches such as genetically engineered T cells with chimeric antigen receptors and T-cell receptors targeting myeloma-specific epitopes, vaccine primed ex vivo expanded autologous T cells, expanded marrow-infiltrating lymphocytes, and plasma cell/dendritic cell fusion vaccines. The addition of these emerging therapies to immunomodulatory drugs and inhibitors of programmed death-1 T-cell regulatory pathways are poised to improve outcome for our patients with myeloma.
authors.affiliation: Division of Hematology-Oncology and the Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
authors.forename: Alfred L
authors.initials: AL
authors.lastname: Garfall
authors.affiliation: Division of Hematology-Oncology and the Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
authors.forename: Edward A
authors.initials: EA
authors.lastname: Stadtmauer
mesh_terms: D019264:Adoptive Transfer; D000818:Animals; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use; D064987:Cell- and Tissue-Based Therapy; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D009101:Multiple Myeloma / Q000276:immunology / Q000628:therapy; D011948:Receptors, Antigen, T-Cell / Q000276:immunology
chemical_list: D019496:Cancer Vaccines; D007155:Immunologic Factors; D011948:Receptors, Antigen, T-Cell